Categories Earnings, Health Care

Earnings Summary: A snapshot of Catalent’s Q3 2023 results

Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third quarter of 2023.

  • The company reported a net loss of $227 million for the third quarter, compared to a profit of $141 million a year earlier
  • On a per-share basis, it was a loss of $1.26 for the March quarter vs. earnings of $0.78 in the year-ago quarter
  • The adjusted net loss was $0.09 per share, compared to net income of $1.04 per share in Q3 2022
  • Third-quarter net revenue decreased 19% year-over-year to $1.04 billion
  • Q3 adjusted EBITDA came in at $105 million, which is down 69% from the corresponding period of 2022
  • For fiscal 2023, the management expects net revenue to be in the range of $4.225 billion to $4.325 billion
  • The forecast for full-year adjusted net income is $169-210 million

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top